Antibiotic use in eyelid surgery varies greatly around globe April 21, 2017By Vanessa CaceresPractice patterns by oculoplastic surgeons for the use of antibiotics with eyelid surgery vary. Surgeons may overestimate the helpfulness of antibiotics.
In this issue
Spectacles saved our republicSometimes, we ophthalmologists—accustomed as we are to high-success rates with our therapeutic interventions—become inured to the impact our efforts can have on patients’ lives. Three reasons for adopting DMEK in routine EK cases July 01, 2017By Steve LenierUsing the Descemet’s membrane endothelial keratoplasty (DMEK) procedure can produce better visual results and lower risk of rejection than using the previous methods (DLEK and DSAEK). The method has become easier to learn and use than in the past, and should be considered as the primary EK procedure for most routine cases of endothelial failure. WFG diagnostic capabilities take entire optical system into account July 01, 2017By Fred GebhartAdvancements in wavefront-guided technology include improved resolution that provides not only better spot quality but also the ability to scan highly aberrated eyes that often did not produce treatable images using earlier technology, according to Edward E. Manche, MD. Nystagmus diagnosis begins with thorough eye exam July 01, 2017By Vanessa CaceresA careful clinical workup, along with genetic testing, can help pinpoint what is behind congenital and infantile nystagmus. ARVO 2017 showcases vision research advancesAdvances in presbyopia, dry eye and allergy, and age-related macular degeneration filled this year’s meeting of the Association for Research in Vision and Ophthalmology. Building on cyclosporine for dry eyeA phase II study investigating a novel topical cyclosporine product (CyclASol, Novaliq) formulated in a semifluorinated alkane (SFA) vehicle showed promising efficacy, safety, and tolerability. Planning is ongoing for the phase III trial of cyclosporine in the SFA technology. Novel therapies abound in pipelineThe importance of novel therapies for ocular disease is a given. However, as most novel therapies are financed by the private sector, it is fortunate that investors find ophthalmology a worthwhile investment. Novel glaucoma drug lowers IOP by unique combination of mechanismsIn a study of normal volunteers, once-daily dosing of netarsudil mesylate ophthalmic solution 0.02% lowered IOP relative to baseline by increasing outflow facility and decreasing episcleral venous pressure.